Key points are not available for this paper at this time.
Too often, the clinical trials that provide the evidence on which drug approvals and medical practices are based fail to offer adequate support for medical decision making, because they include inappropriately narrow and homogeneous study populations. The Journal has begun requiring investigators to report on the representativeness of their study participants, but what are the next steps? In this Perspective Roundtable,
Hwang et al. (Sat,) studied this question.